Atomoxetine Hydrochloride Versus Placebo in Taiwanese Children and Adolescents With ADHD

Phase 3

Completed

• Conditions: Attention Deficit Hyperactivity Disorder

• Registration Number: NCT00485459
• Lead Sponsor: Eli Lilly and Company

Brief Summary

The purpose of this protocol is to investigate the acute treatment efficacy, safety, and tolerability of atomoxetine on a once-daily dosing strategy in Taiwanese children and adolescents with ADHD.

Detailed Description

Not available

Basic Information
|
Recruitment & Eligibility
|
Study & Design
|
Trial Locations

Study Timeline

• Study Start: 2004-02
• Study Completion: 2004-11
• Status Verified: 2007-06
• Study First Submitted: 2007-06-11
• Study First Submitted QC: 2007-06-11
• Last Update Submitted: 2007-06-11
• Study First Posted: 2007-06-13
• Last Update Posted: 2007-06-13

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 106

Inclusion Criteria

• Subject must have ADHD that meet DSM-IV disease diagnostic criteria as well as severity criteria
• Subjects must be aged 6 to 16 years
• Subjects must not have taken any medication used to treat ADHD or they must have completed the washout procedures
• Subjects must be able to swallow capsules
• Subjects must be of normal intelligence in the judgment of the investigator. Normal intelligence is defined as being without evidence of significant general intellectual deficit and expected to achieve a score of 80 or more if formal IQ testing were administered.

Read More

Exclusion Criteria

• Weigh less than 20 kg or more than 60 kg at study entry
• Have a history of Bipolar I or II disorder, psychosis, or pervasive developmental disorder
• Meet DSM-IV criteria for an anxiety disorder as assessed by the investigator
• Have a history of any seizure disorder (other than febrile seizures) or prior ECG abnormalities related to epilepsy, or subjects who have taken (or are currently taking) anticonvulsants for seizure control
• Subjects who have a history of severe allergies to more than 1 class of medications or multiple adverse drug reactions.

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Primary Outcome Measures

Name	Time	Method
Test the hypothesis that atomoxetine administered as a single-daily dose provides superior efficacy compared with placebo in Taiwanese children and adolescents with ADHD

Secondary Outcome Measures

Name	Time	Method
Compare the improvement in symptoms associated with ADHD in children and adolescents achieved by once-daily dosing of atomoxetine or placebo
Compare the reduction in school-related symptoms between atomoxetine and placebo
Assess the safety and tolerability of once-daily dosing of atomoxetine

Trial Locations

Locations (1)

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician; 🇨🇳 Taipei, Taiwan